Retinal Laser Burn Abolishes Ocular Immunity Privilege

视网膜激光烧伤取消了眼部的免疫特权

基本信息

  • 批准号:
    7816665
  • 负责人:
  • 金额:
    $ 5.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-02-06 至 2011-02-05
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The immune response in many areas of the body following trauma is inflammation followed by scarring and repair. In the eye, inflammation and scarring of tissues would greatly reduce and obscure the visual field of an individual. Therefore the eye has evolved into an immune privileged area, thereby inhibiting ocular inflammation. To study immune privilege we use an experimental model termed Anterior Chamber Associated Immune Deviation (ACAID). Recently, we have found that retinal laser burn (RLB) abolishes ACAID. This is of interest because lasers are gaining increase usage for treatment of glaucoma, myopia and Age-related macular degeneration. The purpose of this proposal is to understand the mechanism in RLB mice that lead to the loss of ACAID. We will use knowledge from previous studies that detail components (Aqueous humor, F4/80+ Antigen presenting cells and T-regulatory cells) of the immune system important for ocular immune privilege. AIM 1 will identify changes in the aqueous humor environment that might contribute to the ability to induce ACAID in RLB mice compared to WT mice. AIM 2 will determine if lack of immune privilege in the RLB mice is due to a defect in the F4/80+ ARC. AIM 3 will determine the characteristics of T cells after RLB. This proposal is directly relevant to public health because its findings can lead to improved strategies for treating patients exposed to therapeutic or accidental laser exposure. Moreover, understanding the side effects of laser treatment to the retina will allow for more careful and controlled treatment of patients with diabetic retinopathy, uveitis and age related macular degeneration. Overall, the results of the studies may lead to translational studies that examine the changes in the ocular environment (aqueous humor) of humans who are treated for accidental laser burn, receive RLB in the course treatment for their eye disease or present with post eye trauma or eye surgery.
描述(由申请人提供):创伤后身体许多部位的免疫反应是炎症,随后是瘢痕形成和修复。在眼睛中,组织的炎症和疤痕会大大减少和模糊个人的视野。因此,眼睛已经进化成一个免疫特权区域,从而抑制眼部炎症。为了研究免疫特权,我们使用了前房相关免疫偏差(ACAID)的实验模型。最近,我们发现视网膜激光烧伤(RLB)可以消除ACAID。这是有趣的,因为激光越来越多地用于治疗青光眼、近视和老年性黄斑变性。本提案的目的是了解RLB小鼠导致ACAID丧失的机制。我们将利用先前研究的知识,详细介绍免疫系统中对眼部免疫特权重要的成分(房水、F4/80+抗原提呈细胞和t调节细胞)。AIM 1将确定与WT小鼠相比,RLB小鼠房水环境的变化可能有助于诱导ACAID的能力。AIM 2将确定RLB小鼠缺乏免疫特权是否是由于F4/80+ ARC缺陷所致。AIM 3测定RLB后T细胞的特征。这一建议与公共卫生直接相关,因为其研究结果可以改善治疗暴露于治疗性或意外激光照射的患者的策略。此外,了解激光治疗对视网膜的副作用将使糖尿病视网膜病变、葡萄膜炎和年龄相关性黄斑变性患者的治疗更加谨慎和可控。总的来说,这些研究的结果可能导致转译性研究,以检查因意外激光烧伤而接受治疗的人,在眼病治疗过程中接受RLB的人,或有眼外伤或眼科手术的人的眼环境(房水)的变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kenyatta G Lucas其他文献

Kenyatta G Lucas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kenyatta G Lucas', 18)}}的其他基金

Retinal Laser Burn Abolishes Ocular Immunity Privilege
视网膜激光烧伤取消了眼部的免疫特权
  • 批准号:
    7483417
  • 财政年份:
    2009
  • 资助金额:
    $ 5.22万
  • 项目类别:
Mechanisms underlying NMDA receptor localization
NMDA 受体定位的机制
  • 批准号:
    7054283
  • 财政年份:
    2006
  • 资助金额:
    $ 5.22万
  • 项目类别:

相似海外基金

I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
  • 批准号:
    10102692
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
  • 批准号:
    10639785
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
  • 批准号:
    23K09052
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
  • 批准号:
    10679287
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
  • 批准号:
    10642988
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
  • 批准号:
    10635325
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
  • 批准号:
    10584110
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
  • 批准号:
    22H03243
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
  • 批准号:
    10433610
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
  • 批准号:
    10504138
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了